Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ITOC 2020 | PD-1 and OX40: potential PDAC combination therapy

Cassian Yee • 28 Sep 2020
ITOC 2020
Pancreatic Cancer Antibodies

Cassian Yee, MD, MD Anderson Cancer Center, The University of Texas, Houston, TX, discusses the combination of PD-1 inhibitor with OX40 agonist which induced tumor rejection and immune memory in mice with pancreatic tumors. This information can be used in the development of future immune-based combination therapies for pancreatic ductal adenocarcinoma (PDAC). This interview took place during the 7th Immunotherapy of Cancer Conference (ITOC) 2020.

More from Cassian Yee

HDACi and IL21: reprogramming CD8+ T-cells to memory T-cells
5:07
HDACi and IL21: reprogramming CD8+ T-cells to memory T-cells
Cassian Yee • 28 Sep 2020

Related Videos

Molecular profiling and targeted combination strategies in pancreatic cancer
0:55
Molecular profiling and targeted combination strategies in pancreatic cancer
Zev Wainberg • 25 Oct 2026
RASolute 302: additional subgroup analyses of daraxonrasib in pretreated PDAC
1:30
RASolute 302: additional subgroup analyses of daraxonrasib in pretreated PDAC
Zev Wainberg • 25 Oct 2026
The role of consolidative radiation after induction chemotherapy in pancreatic cancer
1:05
The role of consolidative radiation after induction chemotherapy in pancreatic cancer
Andrew Oar • 23 Oct 2026
Combining SBRT with chemotherapy and KRAS inhibitors in pancreatic cancer
0:40
Combining SBRT with chemotherapy and KRAS inhibitors in pancreatic cancer
Andrew Oar • 23 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals